Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells

[1] Kleeff J(2016)Pancreatic cancer Nat Rev Dis Primers 2 16022-1061

[2] Korc M(2017)Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology J Natl Compr Canc Netw 15 1028-1726

[3] Apte M(2009)AHPBA/SSO/SSAT consensus conference on Resectable and borderline Resectable pancreatic Cancer: rationale and overview of the conference Ann Surg Oncol 16 1725-3650

[4] La Vecchia C(2009)Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma Cancer 115 3640-1081

[5] Johnson CD(2010)Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 1073-257

[6] Biankin AV(2016)Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) Lancet (London, England) 388 248-S30

[7] Neale RE(2007)Treatment of advanced pancreatic cancer Semin Oncol 34 S25-140

[8] Tempero M(1996)Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers Proc Natl Acad Sci U S A 93 136-845

[9] Tuveson DA(2005)Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis Am J Clin Pathol 124 838-296

[10] Hruban RH(2008)Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer Mol Cancer Ther 7 286-142

[1] Kleeff J(2016)Pancreatic cancer Nat Rev Dis Primers 2 16022-1061

[2] Korc M(2017)Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology J Natl Compr Canc Netw 15 1028-1726

[3] Apte M(2009)AHPBA/SSO/SSAT consensus conference on Resectable and borderline Resectable pancreatic Cancer: rationale and overview of the conference Ann Surg Oncol 16 1725-3650

[4] La Vecchia C(2009)Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma Cancer 115 3640-1081

[5] Johnson CD(2010)Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 1073-257

[6] Biankin AV(2016)Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) Lancet (London, England) 388 248-S30

[7] Neale RE(2007)Treatment of advanced pancreatic cancer Semin Oncol 34 S25-140

[8] Tempero M(1996)Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers Proc Natl Acad Sci U S A 93 136-845

[9] Tuveson DA(2005)Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis Am J Clin Pathol 124 838-296

[10] Hruban RH(2008)Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer Mol Cancer Ther 7 286-142